Pablo Jimenez Labaig, Medical Oncologist at The Royal Marsden NHS Fundation Trust, shared a post on LinkedIn:
“Movement on the ground for perioperative pembrolizumab in head and neck (KN689), none for adj nivo (NIVOPOSTOP, one of the 5 plenaries in ASCO25).
News for pembrolizumab:
UK (NICE) In development
Japan (PMDA) In development
Australia (TGA) In development
European Union (EMA) Positive opinion, in progress
South Korea (MFDS) Approved
Canada (HC) Approved
United States (FDA) Approved
Only in PD-L1+
But LMICs also showing promising results from low-dose neo IO-CT.”
Title: Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy
Authors: Josh Thomas Georgy, Soumya Susan Regi, Rosh Varghese Georgy, Balu Krishna Sasidharan, Anjana Joel, Deepa Susan Joy Philip, Ajoy Oommen John, Divya Bala Thumaty, Praveen Kumar Marimuthu, Prashant Jambunathan, Kovilapu Harikrishna, Zachariah Thomas, N. Jansi Rani, Amit Jiwan Tirkey, Meera Thomas, Rajesh Isiah, Ashish Singh
Read the full article in Nature.
More posts featuring Pablo Jimenez Labaig.
